During morning rounds on the cardiology step-down unit, a physician assesses a 72-year-old… — USMLE Step 3

During morning rounds on the cardiology step-down unit, a physician assesses a $72$ -year-old male who complains of excruciating pain in his right big toe that began overnight. The patient was hospitalized $72$ hours ago for volume overload requiring aggressive diuresis with intravenous furosemide. His respiratory status has since stabilized.

Physical examination of the right foot reveals prominent erythema, swelling, and exquisite tenderness localized to the first metatarsophalangeal joint. Arthrocentesis yields synovial fluid containing $35,000 \text{ leukocytes/mm}^3$ ( $90\%$ neutrophils) and numerous negatively birefringent, needle-shaped crystals under polarized light microscopy.

His medical history is significant for ischemic cardiomyopathy (left ventricular ejection fraction $25\%$ ), chronic kidney disease (baseline creatinine $2.1 \text{ mg/dL}$ ), and a life-threatening peptic ulcer bleed $4$ months ago that required endoscopic clipping.

Today's vital signs are within normal limits. Laboratory studies show a current serum creatinine of $2.3 \text{ mg/dL}$ .

Which of the following is the most appropriate targeted pharmacotherapy for this patient's acute joint pathology?

Intra-articular triamcinolone injectionAnswer
B
Oral indomethacin
C
Oral colchicine
D
Intravenous methylprednisolone
E
Oral allopurinol

Answer

Intra-articular triamcinolone injection is the most appropriate pharmacologic intervention.

Intra-articular triamcinolone injection is the correct targeted therapy because it provides potent, localized anti-inflammatory relief for a monoarticular gout flare without causing systemic side effects. This patient's multiple comorbidities—ischemic cardiomyopathy, chronic kidney disease, and a recent severe peptic ulcer bleed—act as absolute or strong relative contraindications to the standard systemic therapies, making a localized injection the only safe choice.

Step-by-Step Solution

Diagnose the acute condition based on clinical presentation and synovial fluid analysis.

The patient has an acute gout flare (podagra), confirmed by monoarticular inflammation and negatively birefringent, needle-shaped monosodium urate crystals.

Accurate diagnosis is required before selecting targeted pharmacotherapy.

Identify the standard first-line pharmacologic options for an acute gout flare.

Standard treatments include NSAIDs (e.g., indomethacin), colchicine, and corticosteroids (systemic or intra-articular).

These agents interrupt the acute inflammatory cascade triggered by the urate crystals.

Cross-reference the standard treatments with the patient's underlying comorbidities to rule out contraindicated therapies.

NSAIDs are contraindicated due to heart failure (fluid retention), chronic kidney disease (hemodynamic AKI), and recent GI bleed. Colchicine is high-risk in advanced CKD. Systemic corticosteroids risk precipitating volume overload in severe HFrEF.

Patient safety requires minimizing systemic adverse effects in a highly vulnerable individual.

Select the optimal remaining therapeutic intervention.

Intra-articular corticosteroid injection (e.g., triamcinolone) is chosen.

It provides potent, localized anti-inflammatory action while completely bypassing the systemic mechanisms that contraindicate the other medications.

Key Concept

In patients with acute monoarticular gout who have multiple comorbidities (such as heart failure, chronic kidney disease, and peptic ulcer disease) that contraindicate systemic NSAIDs, colchicine, and systemic corticosteroids, an intra-articular corticosteroid injection is the safest and most effective pharmacologic intervention.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic